OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection

Citation
Y. Takahashi et al., OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection, J VIROLOGY, 75(15), 2001, pp. 6748-6757
Citations number
47
Categorie Soggetti
Microbiology
Journal title
JOURNAL OF VIROLOGY
ISSN journal
0022538X → ACNP
Volume
75
Issue
15
Year of publication
2001
Pages
6748 - 6757
Database
ISI
SICI code
0022-538X(200108)75:15<6748:OSBGLE>2.0.ZU;2-4
Abstract
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily an d known to be an important costimulatory molecule expressed on activated T cells. To investigate the role of costimulation of OX40 in human immunodefi ciency virus type 1 (HIV-1) infection by its natural ligand, gp34, the OX40 -transfected ACH-2 cell line, ACH-2/OX40, chronically infected with HIV-1, was cocultured with paraformaldehyde (PFA)-fixed gp34-transfected mouse cel l line, SV-T2/gp34. The results showed that HIV-1 production was strongly i nduced. This was followed by apparent apoptosis, and both processes were sp ecifically inhibited by the gp34-specific neutralizing monoclonal antibody 5A8. Endogenous TNF alpha (TNF-alpha) and TNF-beta production were not invo lved in the enhanced HIV-1 production. Furthermore, enhanced HIV-1 transcri ption in gp34-stimulated ACH-2/OX40 cells was dependent on the kappaB Site of the HIV-1 long terminal repeat, and the OX40-gp34 interaction activated NF-kappaB consisting of p50 and p65 subunits. When primary activated CD4(+) T cells acutely infected with HIV-1(NL4-3) (CXCR4-using T-cell-line-tropic ) were cocultured with PFA-fixed gp34(+) human T-cell leukemia virus type 1 -bearing MT-2 cells or SV-T2/gp34 cells, HIV-1 production was also markedly enhanced. The enhancement was again significantly inhibited by 5A8. The pr esent study first shows that OX40-gp34 interaction stimulates HIV-1 express ion and suggests that OX40 triggering by gp34 may play an important role in enhancing HIV-1 production in both acutely and latently infected CD4(+) T cells in vivo.